KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Outstanding (Weighted Average): 2013-2024

Historic Shares Outstanding (Weighted Average) for Aurinia Pharmaceuticals (AUPH) over the last 12 years, with Dec 2024 value amounting to $143.2 million.

  • Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) fell 7.95% to $131.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.6 million, marking a year-over-year decrease of 7.95%. This contributed to the annual value of $143.2 million for FY2024, which is 0.30% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $143.2 million for FY2024, which was down 0.30% from $143.6 million recorded in FY2023.
  • Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $143.6 million during FY2023, with a 5-year trough of $126.5 million in FY2020.
  • For the 3-year period, Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $143.0 million, with its median value being $143.2 million (2024).
  • In the last 5 years, Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) spiked by 34.11% in 2020 and then decreased by 0.30% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $126.5 million in 2020, then climbed by 12.02% to $141.7 million in 2021, then grew by 0.32% to $142.1 million in 2022, then rose by 1.05% to $143.6 million in 2023, then dropped by 0.30% to $143.2 million in 2024.